Prelude Corporation has unveiled data from an analysis of over 700 early-stage invasive breast cancer patients for AidaBreast- a novel biosignature that predicts 10-year recurrence rate and radiation therapy (RT) benefit - at the 41st Annual Miami Breast Cancer Conference (MBCC).
Building on the clinical adoption of the company’s initial test offering, DCISionRT, which predicts radiation benefit for patients with ductal carcinoma in situ (DCIS), AidaBreast will provide personalized testing to the larger Stage I and IIA breast cancer market. AidaBreast is powered by a multi-omic platform utilizing proteomic and genomic analyses, and offers a unique, differentiated approach to determine individual patient risk profiles. The first test in the AidaBreast portfolio will be for the assessment of radiation therapy benefit.
The poster entitled, ‘A Novel Biosignature for Early-Stage Invasive Breast Cancer to Predict Radiotherapy Benefit and Assess Recurrence Risk for Patients Treated with Breast-Conserving Surgery’, demonstrates the potential of the assay to predict radiation benefit in over 700 patients diagnosed with hormone receptor-positive, HER2-negative, Stage I, IIA, node negative, no evidence of metastasis breast cancer who underwent breast conserving surgery (BCS) with or without RT. The biosignature identified clinically meaningful risk groups with differential RT benefit associated with 10-year recurrence rate. The identified low-risk group had a recurrence rate of 1% with or without RT. The elevated risk group had a recurrence rate of 20% without RT and 13% with RT. The residual risk group had a recurrence rate of 30% with or without RT.
